SCHEMBL172469

SCHEMBL172469

COc1ccc(C2CCC(C3CCC(C)CC3)CC2)c(F)c1F

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 2/20 0.34
USP30 Q70CQ3 1/20 0.34
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
PDE5A O76074 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TAS1R3 Q7RTX0 1/20 0.33
TAS1R1 Q7RTX1 1/20 0.33
TAS1R2 Q8TE23 1/20 0.33
POLB P06746 1/20 0.33
MCOLN3 Q8TDD5 1/20 0.33
ADRA1A P35348 2/20 0.33
ALOX5AP P20292 1/20 0.32
FEN1 P39748 1/20 0.32
ALDH1A1 P00352 1/20 0.32
ESR2 Q92731 1/20 0.32
HTR1A P08908 1/20 0.31
SLC6A2 P23975 1/20 0.31
SLC6A4 P31645 1/20 0.31
SLC6A3 Q01959 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL170527 0.95 HTR2C (0.37) HTR2CUSP30TSHRMAPK1PDE5A
SCHEMBL13868125 0.94 ALOX5AP (0.34) USP30ALOX5APFEN1
SCHEMBL803458 0.94 ALOX5AP (0.34) USP30ALOX5APFEN1
SCHEMBL13000031 0.91 ALOX5AP (0.39) ALOX5APFEN1
SCHEMBL16922997 0.89 ALOX5AP (0.36) HTR2CUSP30ALOX5APFEN1
SCHEMBL10035142 0.89 ALOX5AP (0.36) HTR2CUSP30ALOX5APFEN1
SCHEMBL12994249 0.88 HTR2C (0.41) HTR2CUSP30PDE5AADRA1AALOX5AP
SCHEMBL20273235 0.88 ABCB1 (0.38) HTR2CUSP30PDE5AALOX5APFEN1
SCHEMBL12075626 0.88 ABCB1 (0.38) HTR2CUSP30PDE5AALOX5APFEN1
SCHEMBL26045652 0.88 ABCB1 (0.38) HTR2CUSP30PDE5AALOX5APFEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 424 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024133363-A1 LIQUID-CRYSTAL MEDIUM MERCK PATENT GMBH (DE) 2024-06-27 WO disclosed
WO-2024017812-A1 LIQUID CRYSTALLINE MEDIUM MERCK PATENT GMBH (DE) 2024-01-25 WO disclosed
EP-4306615-A1 LIQUID-CRYSTAL MEDIUM Merck Patent GmbH (DE) 2024-01-17 EP disclosed
US-11873438-B2 Liquid-crystal medium MERCK PATENT GMBH (DE) 2024-01-16 US disclosed
EP-4279565-A2 THIOPHENE COMPOUND, LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME Merck Patent GmbH (DE) 2023-11-22 EP disclosed
US-20230357637-A1 LIQUID-CRYSTAL MEDIUM MERCK PATENT GMBH (DE) 2023-11-09 US disclosed
US-20230357637-A1 LIQUID-CRYSTAL MEDIUM MERCK PATENT GMBH (DE) 2023-11-09 US disclosed
EP-4273207-A1 LIQUID-CRYSTAL MEDIUM Merck Patent GmbH (DE) 2023-11-08 EP disclosed
EP-3679111-B1 LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME MERCK PATENT GMBH (DE) 2023-11-01 EP disclosed
US-11802243-B2 Liquid-crystal medium MERCK PATENT GMBH (DE) 2023-10-31 US disclosed
WO-2009115186-A1 LIQUID CRYSTALLINE MEDIUM MERCK PATENT GMBH (DE) 2009-09-24 WO disclosed
US-20090103011-A1 LIQUID-CRYSTAL MEDIUM MERCK PATENT GESELLSCHAFT (DE) 2009-04-23 US disclosed
US-20090023802-A1 Benzochromene Derivatives MERCK PATENT GMBH (DE) 2009-01-22 US disclosed
US-20080308768-A1 Liquid Crystalline Medium MERCK PATENT GMBH (DE) 2008-12-18 US disclosed
US-7440160-B2 Electro-optical light modulating element, electro-optical display and modulating medium MERCK PATENT GMBH (DE) 2008-10-21 US disclosed
EP-1362839-B1 Liquid crystal composition having a positive delta-epsilon and liquid crystal display device CHISSO CORP (JP) 2008-08-13 EP disclosed
US-20080177095-A1 FUROCHROMAN DERIVATIVES MERCK PATENT GMBH (DE) 2008-07-24 US disclosed
US-7371437-B2 Liquid-crystalline medium MERCK PATENT GMBH (DE) 2008-05-13 US disclosed
US-20080090026-A1 Liquid-crystal display MERCK PATENT GMBH 2008-04-17 US disclosed
WO-2008009417-A1 LIQUID CRYSTALLINE MEDIUM MERCK PATENT GMBH (DE) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080177095-A1 FUROCHROMAN DERIVATIVES CFD, LMAN1, UROD HTR2C 1360/4885USP30 4826/4885TSHR 3754/4885
US-20080090026-A1 Liquid-crystal display KLK3, LPXN, BPHL HTR2C 1738/4885USP30 2486/4885TSHR 4657/4885
US-20090023802-A1 Benzochromene Derivatives SBDS, CRY1, DDT HTR2C 615/4885USP30 4733/4885TSHR 3974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.